Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma

D. J. Gottlieb, Y. C. Li, I. Lionello, S. Tanzarella, M. Marangolo, K. F. Bradstock, V. Russo, C. Traversari

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lymphodepletion and infusion of autologous expanded tumour-infiltrating lymphocytes is effective therapy for patients with malignant melanoma. Antitumour responses are likely to be mediated by HLA class I- and II-restricted immune responses directed at tumour antigens. We assessed whether the peripheral blood of normal HLA-matched siblings of patients with melanoma could be used to generate lymphocytes with antimelanoma activity for adoptive immunotherapy after allogeneic blood or marrow transplantation. Melanoma cell lines were derived from two donors and were used to stimulate the mononuclear cells of three HLA-identical siblings. CD4+ clones dominated cultures. Of these, approximately half were directly cytotoxic towards recipient melanoma cells and secreted interferon-γ in response to tumour stimulation. More than half of the noncytotoxic clones also secreted interferon-γ after melanoma stimulation. No CD4+ clones responded to stimulation with recipient haemopoietic cells. The majority of CD8+ clones directly lysed recipient melanoma, but did not persist in long-term culture in vitro. No crossreactivity with recipient haemopoietic cells was observed. The antigenic target of one CD4+ clone was determined to be an HLA-DR11-restricted MAGE-3 epitope. Antigenic targets of the remaining clones were not elucidated, but appeared to be restricted through a non-HLA-DR class II molecule. We conclude that the blood of allogeneic HLA-matched sibling donors contains melanoma-reactive lymphocyte precursors directed at tumour-associated antigens. Adoptive immunotherapy with unselected or ex vivo-stimulated donor lymphocytes after allogeneic stem cell transplantation has a rational basis for the treatment of malignant melanoma.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalBritish Journal of Cancer
Volume95
Issue number2
DOIs
Publication statusPublished - Jul 17 2006

Fingerprint

Histocompatibility Antigens
HLA Antigens
Siblings
Melanoma
Clone Cells
T-Lymphocytes
Neoplasms
Adoptive Immunotherapy
Tissue Donors
Neoplasm Antigens
Lymphocytes
Interferons
Tumor-Infiltrating Lymphocytes
Stem Cell Transplantation
Epitopes
Transplantation
Bone Marrow
Cell Line
Therapeutics

Keywords

  • Human
  • Melanoma
  • T cells
  • Transplantation
  • Tumour immunity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gottlieb, D. J., Li, Y. C., Lionello, I., Tanzarella, S., Marangolo, M., Bradstock, K. F., ... Traversari, C. (2006). Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma. British Journal of Cancer, 95(2), 181-188. https://doi.org/10.1038/sj.bjc.6603243

Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma. / Gottlieb, D. J.; Li, Y. C.; Lionello, I.; Tanzarella, S.; Marangolo, M.; Bradstock, K. F.; Russo, V.; Traversari, C.

In: British Journal of Cancer, Vol. 95, No. 2, 17.07.2006, p. 181-188.

Research output: Contribution to journalArticle

Gottlieb, D. J. ; Li, Y. C. ; Lionello, I. ; Tanzarella, S. ; Marangolo, M. ; Bradstock, K. F. ; Russo, V. ; Traversari, C. / Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma. In: British Journal of Cancer. 2006 ; Vol. 95, No. 2. pp. 181-188.
@article{5800df8c81a643cfba0182c174438803,
title = "Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma",
abstract = "Lymphodepletion and infusion of autologous expanded tumour-infiltrating lymphocytes is effective therapy for patients with malignant melanoma. Antitumour responses are likely to be mediated by HLA class I- and II-restricted immune responses directed at tumour antigens. We assessed whether the peripheral blood of normal HLA-matched siblings of patients with melanoma could be used to generate lymphocytes with antimelanoma activity for adoptive immunotherapy after allogeneic blood or marrow transplantation. Melanoma cell lines were derived from two donors and were used to stimulate the mononuclear cells of three HLA-identical siblings. CD4+ clones dominated cultures. Of these, approximately half were directly cytotoxic towards recipient melanoma cells and secreted interferon-γ in response to tumour stimulation. More than half of the noncytotoxic clones also secreted interferon-γ after melanoma stimulation. No CD4+ clones responded to stimulation with recipient haemopoietic cells. The majority of CD8+ clones directly lysed recipient melanoma, but did not persist in long-term culture in vitro. No crossreactivity with recipient haemopoietic cells was observed. The antigenic target of one CD4+ clone was determined to be an HLA-DR11-restricted MAGE-3 epitope. Antigenic targets of the remaining clones were not elucidated, but appeared to be restricted through a non-HLA-DR class II molecule. We conclude that the blood of allogeneic HLA-matched sibling donors contains melanoma-reactive lymphocyte precursors directed at tumour-associated antigens. Adoptive immunotherapy with unselected or ex vivo-stimulated donor lymphocytes after allogeneic stem cell transplantation has a rational basis for the treatment of malignant melanoma.",
keywords = "Human, Melanoma, T cells, Transplantation, Tumour immunity",
author = "Gottlieb, {D. J.} and Li, {Y. C.} and I. Lionello and S. Tanzarella and M. Marangolo and Bradstock, {K. F.} and V. Russo and C. Traversari",
year = "2006",
month = "7",
day = "17",
doi = "10.1038/sj.bjc.6603243",
language = "English",
volume = "95",
pages = "181--188",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma

AU - Gottlieb, D. J.

AU - Li, Y. C.

AU - Lionello, I.

AU - Tanzarella, S.

AU - Marangolo, M.

AU - Bradstock, K. F.

AU - Russo, V.

AU - Traversari, C.

PY - 2006/7/17

Y1 - 2006/7/17

N2 - Lymphodepletion and infusion of autologous expanded tumour-infiltrating lymphocytes is effective therapy for patients with malignant melanoma. Antitumour responses are likely to be mediated by HLA class I- and II-restricted immune responses directed at tumour antigens. We assessed whether the peripheral blood of normal HLA-matched siblings of patients with melanoma could be used to generate lymphocytes with antimelanoma activity for adoptive immunotherapy after allogeneic blood or marrow transplantation. Melanoma cell lines were derived from two donors and were used to stimulate the mononuclear cells of three HLA-identical siblings. CD4+ clones dominated cultures. Of these, approximately half were directly cytotoxic towards recipient melanoma cells and secreted interferon-γ in response to tumour stimulation. More than half of the noncytotoxic clones also secreted interferon-γ after melanoma stimulation. No CD4+ clones responded to stimulation with recipient haemopoietic cells. The majority of CD8+ clones directly lysed recipient melanoma, but did not persist in long-term culture in vitro. No crossreactivity with recipient haemopoietic cells was observed. The antigenic target of one CD4+ clone was determined to be an HLA-DR11-restricted MAGE-3 epitope. Antigenic targets of the remaining clones were not elucidated, but appeared to be restricted through a non-HLA-DR class II molecule. We conclude that the blood of allogeneic HLA-matched sibling donors contains melanoma-reactive lymphocyte precursors directed at tumour-associated antigens. Adoptive immunotherapy with unselected or ex vivo-stimulated donor lymphocytes after allogeneic stem cell transplantation has a rational basis for the treatment of malignant melanoma.

AB - Lymphodepletion and infusion of autologous expanded tumour-infiltrating lymphocytes is effective therapy for patients with malignant melanoma. Antitumour responses are likely to be mediated by HLA class I- and II-restricted immune responses directed at tumour antigens. We assessed whether the peripheral blood of normal HLA-matched siblings of patients with melanoma could be used to generate lymphocytes with antimelanoma activity for adoptive immunotherapy after allogeneic blood or marrow transplantation. Melanoma cell lines were derived from two donors and were used to stimulate the mononuclear cells of three HLA-identical siblings. CD4+ clones dominated cultures. Of these, approximately half were directly cytotoxic towards recipient melanoma cells and secreted interferon-γ in response to tumour stimulation. More than half of the noncytotoxic clones also secreted interferon-γ after melanoma stimulation. No CD4+ clones responded to stimulation with recipient haemopoietic cells. The majority of CD8+ clones directly lysed recipient melanoma, but did not persist in long-term culture in vitro. No crossreactivity with recipient haemopoietic cells was observed. The antigenic target of one CD4+ clone was determined to be an HLA-DR11-restricted MAGE-3 epitope. Antigenic targets of the remaining clones were not elucidated, but appeared to be restricted through a non-HLA-DR class II molecule. We conclude that the blood of allogeneic HLA-matched sibling donors contains melanoma-reactive lymphocyte precursors directed at tumour-associated antigens. Adoptive immunotherapy with unselected or ex vivo-stimulated donor lymphocytes after allogeneic stem cell transplantation has a rational basis for the treatment of malignant melanoma.

KW - Human

KW - Melanoma

KW - T cells

KW - Transplantation

KW - Tumour immunity

UR - http://www.scopus.com/inward/record.url?scp=33745926544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745926544&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603243

DO - 10.1038/sj.bjc.6603243

M3 - Article

VL - 95

SP - 181

EP - 188

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -